ATXS – astria therapeutics, inc. (US:NASDAQ)

News

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush.
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com